SITC

SITC 2024 Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024 Donwload Press release (PDF) Donwload the Poster (PDF)

Presentation

Transgene in a nutshell Download(PDF)   Corporate Presentation Download(PDF)   Universal Registration Document Download(PDF)

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00

 

© 2025 Transgene - All rights reserved
Credits